Farma

focuss
PHO 22.07.2019 kl 23:39 9848

Fra Q1 rapporten
It is our ambition to make Hexvix/Cysview the standard of care for bladder cancer patients. Keys to Success are in place:

• Approval – Broader US Indication into the 3x larger surveillance market
• Acceptance - AUA, EAU, SUO and many regional and local guidelines as well as the newly published Expert Consensus Guidelines for surveillance with flexible cystoscopes
• Access - Permanent and favorable reimbursement as of January 2019
• Activated Awareness – Patient demand via advocacy groups and media; 99% of bladder cancer patients in a recent survey intend to seek institutions offering BLC
• Acceleration – Commercial investment in the US to optimize the opportunity in our largest and untapped market

We will maximize the return on our commercial investment by executing our plans in the largely untapped U.S market where we expect to see our greatest returns in the form of significant and sustainable revenue and profitability growth.”

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.